Talquetamab delivers high response rates in refractory myeloma; learn how to prevent skin, nail and oral side effects to stay on therapy. As the therapeutic arsenal for relapsed/refractory multiple ...
Adding lenvatinib to pembrolizumab improved PFS (6.2 vs 2.8 months; HR 0.64) and ORR (46.1% vs 25.4%) versus pembrolizumab alone in PD-L1 CPS ≥1 disease. Overall survival was not improved at 21.3 ...
FDA approval extends nivolumab into first-line stage III/IV cHL in adults and pediatrics, following priority review of the supplemental application for nivolumab plus AVD. SWOG S1826 showed superior ...
Severe CRS appeared numerically less frequent than in ZUMA-3, suggesting potential differences in patient selection, supportive care, grading, or real-world mitigation strategies. Tocilizumab and ...
Building on her discovery of the GLP-1 signaling pathway's role in sarcoma biology, Erica Pimenta, MD, PhD, of the Dana-Farber Cancer Institute, is exploring the therapeutic poten ...
Benefit was maintained across MZL subtypes and subgroups, including splenic MZL, with particularly favorable 24-month outcomes among patients achieving complete response. Safety signals aligned with ...
NCCN upgraded support to category 2A for BCG-unresponsive high-grade papillary Ta/T1 without CIS, while maintaining category ...
Lymphoma care still leaves gaps—research aims for higher cure rates, longer remission, and fewer toxicities across B-, T-cell and Hodgkin.
In this episode of The OncoloGIST, breast cancer oncologist and clinical researcher Dr Paolo Tarantino of Dana-Farber Cancer Institute reflects on how antibody-drug conjugates (AD ...
A randomized phase 2 maintenance strategy with cabozantinib 60 mg daily for up to 2 years failed to improve 4-month PFS versus placebo in high-grade uterine sarcomas. Median PFS was identical at 3.7 ...
Genetic assays have transformed how clinicians approach treatment decisions in breast cancer, offering both predictive and prognostic insight that helps tailor therapy to individu ...
The FDA has granted orphan drug designation (ODD) to a locally delivered formulation of irinotecan (ChemoSeed) for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results